From Basic Research to Clinical Practice

Cooperation between HI-STEM and Heidelberg University Hospital Departments


Heidelberg University Hospital Departments

Prof. Müller-Tidow


Medical Clinic V - Hematology – Oncology – Rheumatology

Prof. Dr. Carsten Müller-Tidow, Medical Director

Professor Müller-Tidow is one of HI-STEM's privileged clinical partners. This cooperation serves to further optimize and connect the collaboration between cutting edge clinical and basic research.






Department of Urology

Professor Dr. med. Markus Hohenfellner, Medical Director

The goal of this cooperation is to identify and combat prostate cancer stem cells. Dr. Thomas Höfner, a surgeon on Prof. Hohenfellner's staff, is currently analyzing tumor samples at HI-STEM using modern molecular techniques.


Women’s Hospital

Prof. Dr. Andreas Schneeweiss, Dr. Frederik Marmé, Head of the Working Group, and Prof. Dr. Barbara Burwinkel 

This group is conducting a large-scale study in which metastatic cancer stem cells in blood samples from 600 breast cancer patients will be measured and studied by molecular analysis. In a second study, investigators will search for cancer stem cells in ovarian tumors.




Department of General, Visceral and Transplantation Surgery

Prof. Dr. med. Jens Werner, MBA,
First Senior Physician and Director of the Pancreatic Surgery Unit 

The goal of this study is to decipher the reasons for the rapid metastasis of pancreatic cancer to the liver and to tackle this problem


Mannheim University Hospital



Medical Clinic III – Hematology and Internal Oncology

Prof. Dr. med. Wolf-K. Hofmann, Director

These investigators are investigating a murine model of myelodysplastic syndrome, a form of blood cancer. The goal is to gain a better understanding of the cellular and biological causes of this type of cancer, which originates in stem cells, in order to better treat the disease.




Department of Dermatology, Venerology and Allergology

Dr. Jochen Utikal

In this collaboration, researchers will investigate the role of cancer gene Myc in the reprogramming of skin cells into induced pluripotent stem cells (iPS cells).



Jena University Hospital



Clinic for Internal Medicine II -Department of Hematology and Internal Oncology

Prof. Dr. med. Andreas Hochhaus, Director of the Department

In this planned study of patients with chronic myelogenous leukemia (CML), researchers will soon investigate whether leukemia stem cells can be killed by successive combina- tion treatments consisting of interferons and tyrosine kinase inhibitors. If successful, this treatment could result in cure.


Düsseldorf University Hospital



Prof. Dr. Rainer Haas, Director

In this project, the effects of multiple myeloma cells in patient samples on stem cell niches will be investigated using innovative murine models.